REVLIMID® (lenalidomide) is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1–risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

Help patients with MDS stay on therapy with dose modifications1

Cytopenias are associated with REVLIMID® (lenalidomide) in MDS and should be monitored closely. Dose adjustments are expected in the initial cycles of therapy and may help manage cytopenias.


Dose Adjustments for Hematologic Toxicities Dose Adjustments for Hematologic Toxicities

Dose modifications for non-hematologic adverse reactions

  • For non-hematologic Grade 3/4 toxicities judged to be related to REVLIMID, hold treatment and restart at the physician’s discretion at next lower dose level when toxicity has resolved to Grade 2 or below.
  • Permanently discontinue REVLIMID for angioedema, anaphylaxis, Grade 4 rash, skin exfoliation, bullae, or any other severe dermatologic reactions.

See dose reductions and interruptions from the clinical trial.

See Dose Modifications